BiotechTube

zorevunersen

Phase 3Recruiting
0 watching 0 views this week📈 Rising
72
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Dravet Syndrome

Conditions

Dravet Syndrome

Trial Timeline

Jun 4, 2025 → Oct 1, 2028

NCT ID
NCT06872125

About zorevunersen

zorevunersen is a phase 3 stage product being developed by Stoke Therapeutics for Dravet Syndrome. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06872125. Target conditions include Dravet Syndrome.

Hype Score Breakdown

Clinical
27
Activity
18
Company
5
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT06872125Phase 3Recruiting

Competing Products

15 competing products in Dravet Syndrome

See all competitors
ProductCompanyStageHype Score
ZX008 (Fenfluramine Hydrochloride)UCBPhase 3
74
ZX008 (Fenfluramine Hydrochloride)UCBPhase 3
74
ZX008 0.2 to 0.8 mg/kg/day + CannabidiolUCBPhase 1
30
fenfluramineUCBApproved
82
Fenfluramine HydrochlorideUCBPre-clinical
20
ZX008 (Fenfluramine Hydrochloride) + Matching PlaceboUCBPhase 3
74
ZX008 (Fenfluramine Hydrochloride)UCBPhase 3
74
fenfluramineUCBPhase 3
74
ZX008 (Fenfluramine Hydrochloride) + Matching PlaceboUCBPhase 3
74
ClobazamLundbeckPhase 3
74
Clobazam + PlaceboLundbeckPhase 3
74
Epidiolex 100 mg/mL Oral SolutionJazz PharmaceuticalsApproved
82
STK-001 - Single Ascending Doses + STK-001 - Multiple Ascending DosesStoke TherapeuticsPhase 1/2
36
zorevunersen (STK-001)Stoke TherapeuticsPhase 2
47
Clemizole HCl + PlaceboHarmony BiosciencesPhase 3
72

Other Products from Stoke Therapeutics

zorevunersen (STK-001)Phase 2
47
STK-001 - Single Ascending Doses + STK-001 - Multiple Ascending DosesPhase 1/2
36